Back to first-pass browser

First-pass extracted concept

therapy-induced senescence

Candidate: concept label1 source documents5 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

TIS

Evidence Snippets

Therapy-induced senescence (TIS) generates an immunogenic state in cancer cells
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1assay findingsupports2025Source 1DOIPubMed

BH3 profiling assessments have revealed that therapy-induced senescent cancer cells are globally less primed for apoptosis than their proliferating precursors.

Quoted textsource-backed
recent assessments of mitochondrial apoptotic signaling via BH3 profiling ... have revealed that TIS cancer cells are globally less primed for apoptosis than their proliferating precursors
Claim 2dependency claimsupports2025Source 1DOIPubMed

Therapy-induced senescent cancer cells exhibit a conserved, druggable dependence on specific BCL-2 family members for survival.

Quoted textsource-backed
TIS cancer cells exhibit a conserved, druggable dependence on specific members of the BCL-2 family for survival.
Claim 3mechanistic insightsupports2025Source 1DOIPubMed

Pre-existing mitochondrial priming and anti-apoptotic dependencies of parental non-senescent cells are retained after senescence induction, suggesting an inherited mitochondrial memory.

Quoted textsource-backed
the pre-existing priming and anti-apoptotic addictions of parental, non-senescent cells, are retained upon induction of senescence. This suggests an "inherited" mitochondrial memory
Claim 4mechanistic insightsupports2025Source 1DOIPubMed

Therapy-induced senescence generates an immunogenic state in cancer cells by altering antigen presentation, cytokine production, and surfaceome organization.

Quoted textsource-backed
Therapy-induced senescence (TIS) generates an immunogenic state in cancer cells by altering how they present antigens, produce cytokines, and organize their surfaceome.
Claim 5therapeutic rationalesupports2025Source 1DOIPubMed

Therapy-induced senescence can be therapeutically exploited using immunosenolytic strategies including CAR-engineered T cells and NK cells.

Quoted textsource-backed
TIS can be exploited for therapeutic purposes using "immunosenolytic" strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells.